JP MORGAN ASSET MANAGEMENT HOLDINGS ANNOUNCE 3.33% SHAREHOLDING IN ABLYNX

REGULATED INFORMATION              

GHENT, Belgium, Dec. 2, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from JP Morgan Asset Management Holdings Inc. and JP Morgan Asset Management (UK) Limited.

The above shareholders notified that they have exceeded the 3% threshold and now hold 1,813,725 Ablynx shares, which represent 3.33% of the current 54,517,624 outstanding Ablynx shares.

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceutical Co., Ltd. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx: Dr Edwin Moses CEO t:   +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e:  [email protected]

Marieke Vermeersch Associate Director Investor Relations t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  [email protected] Follow us on Twitter @AblynxABLX

Ablynx media relations Instinctif Partners: Sue Charles, Daniel Gooch London office t: +44 (0)20 7866 7905 e: [email protected]

Belgium/Dutch and French language Jim Rusagara Brussels office t: +32 (0)2 626 9500 e: [email protected]

Pdf version of the press release http://hugin.info/137912/R/1970614/720464.pdf

HUG#1970614

You May Also Be Interested In

• Jessie Nudelman Joins Habbas & Associates
• Joshu Achieves SOC 2 Type II Recertification
• CliniOps Awarded Patent for an Innovative Offline/Online eSource, or Direct Data Collection (DDC) System, for Global Clinical Trials